Compass Pathways shares webcast updates on Phase 3 trial MADRS curves for psilocybin therapy

Psilocybin-focused Phase 3 trial outcomes are the focus, with Compass Pathways sharing a fuller picture of MADRS symptom score curves via a webcast. The update emphasizes how the MADRS trajectory looks across the study follow-up, using the curves as the main way to communicate changes in depressive symptom severity over time. The webcast format suggests a targeted investor and stakeholder briefing on efficacy evidence quality, helping audiences interpret what the next stage of the Phase 3 dataset implies for clinical development and potential regulatory conversations.